Cadrenal (CVKD) Insider Plans Sale of 1,693 Founders' Shares

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 reporting a proposed public sale of 1,693 common shares valued at $23,634.28 to be sold through Morgan Stanley Smith Barney LLC on 10/09/2025 on NASDAQ. The shares were originally issued as founders' shares on 05/17/2022 and were acquired from the issuer.

The filing also lists multiple recent 10b5-1 plan sales by the same seller totaling several thousand shares over 08/27/2025–10/06/2025, including a single sale of 10,900 shares on 09/25/2025 for $153,182.06. The filer attests there is no undisclosed material information and identifies the broker and planned sale date.

Positive

• Clear disclosure of proposed sale of 1,693 shares valued at $23,634.28
• Broker and exchange identified (Morgan Stanley Smith Barney LLC; NASDAQ) enabling verification
• Use of 10b5-1 plan for prior sales provides pre-established trading framework

Negative

• Substantial recent insider sales including 10,900 shares on 09/25/2025 (gross proceeds $153,182.06) which increase near-term share supply
• Founders' shares being sold (originally issued 05/17/2022), which may be viewed negatively by some investors

Insights

Insider Transactions Analyst

TL;DR: An insider plans to sell 1,693 shares; several recent 10b5-1 sales occurred including 10,900 shares on 09/25/2025.

The notice shows a proposed brokered sale of 1,693 common shares valued at $23,634.28 and confirms the shares were acquired as founders' shares on 05/17/2022. The seller used a brokered transaction through Morgan Stanley Smith Barney LLC and markets the sale on NASDAQ.

Recent executed 10b5-1 sales are listed with exact dates and gross proceeds; notable is a large block of 10,900 shares on 09/25/2025. These facts are directly monitorable and relevant for short-term share-supply dynamics.

Corporate Governance Specialist

TL;DR: Filing shows formal compliance with Rule 144 and 10b5-1 disclosures and includes the required attestation about material nonpublic information.

The form includes the required attestation that the seller is not aware of any undisclosed material adverse information and records the adoption or reliance on a written trading plan where applicable. This demonstrates procedural compliance with trading and disclosure rules.

Stakeholders can track announced sale dates and compare them to future filings to confirm completion; the listed broker and precise sale date 10/09/2025 provide concrete checkpoints for verification.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1693	23634.28	2046854	10/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/17/2022	Founders Shares	Issuer			1693	05/17/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	10/06/2025	107	1496.93
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	10/01/2025	1700	23786.06
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/29/2025	100	1400.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/25/2025	10900	153182.06
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	09/24/2025	1500	20992.95
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/28/2025	400	5600.00
10b5-1 Sales for MATTHEW SZOT 822 A1A North, Suite 306 Ponte Vedra FL 32082	Common	08/27/2025	1600	22392.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does CVKD's Form 144 report about the proposed sale?

It reports a proposed sale of 1,693 common shares valued at $23,634.28 via Morgan Stanley Smith Barney LLC on 10/09/2025 on NASDAQ.

When were the shares to be sold originally acquired?

The shares were acquired as founders' shares on 05/17/2022 and the filing lists the acquisition source as the issuer.

Has the filer sold other CVKD shares recently?

Yes. The filing lists multiple 10b5-1 sales between 08/27/2025 and 10/06/2025, including 10,900 shares sold on 09/25/2025 for $153,182.06.

Which broker will execute the proposed sale?

The filing names Morgan Stanley Smith Barney LLC at 1 New York Plaza, 8th Floor, New York, NY as the executing broker.

Does the filer attest to having material undisclosed information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.